接受永久性粒子植入的前列腺癌患者按前列腺体积分层的预后:是否应因前列腺体积过小(<15 cc)而顾虑近距离放疗?
基于日本前瞻性队列J-POPS中6652例接受永久性粒子植入(±外照射±激素治疗)的前列腺癌患者,按前列腺体积<15 cc、15-20 cc、>20 cc分层,中位随访60.0个月,5年生化失败自由率、前列腺癌特异性死亡率、全因死亡率三组间均无显著差异,前列腺体积与这些结局及2级毒性均无关。
要点
- 前列腺体积<15 cc、15-20 cc、>20 cc三组5年bFFF、PCSM、ACM均无显著差异。
- 单因素及多因素分析中前列腺体积与bFFF、PCSM、ACM及2级毒性均无关。
- 活检阳性百分比是所有治疗结局唯一最显著的预测因素。
核心结论
- 基于日本大型前瞻性数据库分析,按前列腺体积<15 cc、15-20 cc、>20 cc分层,治疗结局无差异。
- 研究证实,前列腺体积小(甚至<15 cc)时行永久性粒子植入仍是一种有效的治疗选择。
研究设计与样本
- 日本前瞻性队列研究(J-POPS),2005年至2011年共6721例,分析人群6652例。
- 患者接受永久性粒子植入±外照射放疗±激素治疗,按前列腺体积分为<15 cc、15-20 cc、>20 cc三组。
- 采用Phoenix定义和Cox比例风险模型评估前列腺体积对生化失败自由率、前列腺癌特异性死亡率和全因死亡率的影响。
主要发现
- 中位随访60.0个月,三组例数分别为491例(7.4%)、1118例(16.8%)、5043例(75.8%)。
- 5年生化失败自由率分别为94.7%、96.2%、95.7%(p=0.407),三组间无差异。
- 5年前列腺癌特异性死亡率分别为99.8%、99.7%、99.8%(p=0.682),三组间无差异。
- 5年全因死亡率分别为98.2%、96.7%、97.2%(p=0.119),三组间无差异。
- 单因素和多因素分析中,前列腺体积与生化失败自由率、前列腺癌特异性死亡率、全因死亡率或2级毒性均无关;活检阳性百分比是所有治疗结局唯一最显著的预测因素。
临床怎么用
- 作者认为,前列腺体积小(甚至<15 cc)时行永久性粒子植入仍是一种有效的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the treatment outcomes of different prostate volumes (PVs), <15 cc, 15-20 cc, and > 20 cc, in patients with prostate cancer who underwent permanent seed implantation (PI) ± external beam radiation therapy ± hormone therapy in a national Japanese prospective cohort study (J-POPS). METHODS AND MATERIALS: Of the 6721 patients in J-POPS from 2005 to 2011, 6652 were included in the analysis population. We categorized the patients into the following three PV groups: <15 cc, 15-20 cc, and > 20 cc. We evaluated the effect of PV on biochemical freedom from failure (bFFF), prostate cancer-specific mortality (PCSM), and all-cause mortality (ACM) using the Phoenix definition and Cox proportional hazard models. RESULTS: The median follow-up period was 60.0 months. Patients in each PV group was 491 (7.4%), 1118 (16.8%), and 5043 (75.8%), respectively. No difference was observed in bFFF (94.7%, 96.2%, and 95.7%, p = 0.407), PCSM (99.8%, 99.7%, and 99.8%, p = 0.682), and ACM (98.2%, 96.7%, and 97.2%, p = 0.119) at 5 years for each PV group. In univariate and multivariate analyses, PV was not associated with bFFF, PCSM, ACM, or grade 2 toxicity. The percentage of positive biopsies was the single most significant predictor for all treatment outcomes. CONCLUSIONS: Our results obtained by analyzing a very large Japanese prospective database showed no difference in treatment outcomes according to PV (<15 cc, 15-20 cc, and ˃20 cc). Our study confirmed that PI in small prostates (even < 15 cc) remains an effective treatment option.
引用
- Masui K, Katayama N, Yorozu A, et al. The prognosis of patients with prostate cancer receiving permanent seed implantation stratified by prostate volume: Should we be reluctant to treat with brachytherapy because of a very small prostate (<15 cc)? Radiother Oncol. 2023. PMID: 37597804. doi:10.1016/j.radonc.2023.109855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。